Anheuser-Busch InBev SA/NV (BUD) Stock Analysis
Is BUD a good investment?
Anheuser-Busch InBev SA/NV (BUD) has a Plutrex AI rating of 77.0/100 as of August 21, 2026, indicating a Buy consensus. The stock is not classified as halal-compliant. Key strength: Valuation anomaly: PEG of 1.18 is 26.5% below the industry average of 1.605, and P/E of 16.78x is 17.3% below the industry average of 20.30x — BUD is the sector's fastest EPS grower (13.4% 5-year CAGR, double industry's 6.67%) trading at the deepest discount, with 25.7% upside to analyst consensus target of $98.23. Main concern: E.P.S. shareholder selling 10 million shares (headline: 'Budweiser-maker AB InBev shareholder E.P.S. to sell 10 million shares in company') continues to create supply overhang — stock has declined -2.9% from $80.23 to $77.92 since prior report, confirming ongoing technical pressure; technical momentum is negative with the stock in a downtrend.
Investment Summary
Anheuser-Busch InBev (BUD) at $77.92 remains a fundamentally compelling Buy with a 25.7% upside to the analyst consensus target of $98.23. The stock trades at a P/E of 16.78x — a 17.3% discount to the industry average of 20.30x — and a PEG of 1.18 versus the industry average of 1.605 (26.5% discount), despite projecting 5-year EPS growth of 13.4% that is double the industry average of 6.67%. FCF of $10.693 billion (~13.7% FCF yield at current market cap) and $8.011 billion in cash provide exceptional financial resilience. The Zacks upgrade to Buy (headline: 'Anheuser-Busch Inbev (BUD) Upgraded to Buy') and volume recovery (headline: 'AB InBev's Volumes Return to Growth') reinforce the fundamental thesis. The primary near-term headwind remains the E.P.S. shareholder selling 10 million shares (headline: 'Budweiser-maker AB InBev shareholder E.P.S. to sell 10 million shares in company'), which has contributed to a -2.9% price decline from $80.23 to $77.92 since the prior report — creating a modestly better entry point without altering the thesis. The stock has now declined approximately -7.4% from the prior prior report level, improving the risk/reward materially.
Key Strengths
- Valuation anomaly: PEG of 1.18 is 26.5% below the industry average of 1.605, and P/E of 16.78x is 17.3% below the industry average of 20.30x — BUD is the sector's fastest EPS grower (13.4% 5-year CAGR, double industry's 6.67%) trading at the deepest discount, with 25.7% upside to analyst consensus target of $98.23
- FCF of $10.693 billion (~13.7% FCF yield) with $8.011 billion cash provides unmatched capital allocation flexibility — simultaneously servicing D/E of 0.74 debt, funding dividends, and enabling buybacks; Zacks upgrade to Buy and volume recovery headlines confirm execution momentum
- Profitability dominance: net margin of 14.9% is 152.5% above the industry average of 5.90%, gross margin 56.5% (+15.5% vs. peers), operating margin 27.34% (+21.8% vs. peers) — structurally defensible moat across 500+ brand global portfolio with $13M Baldwinsville brewery expansion signaling continued domestic investment
Key Concerns
- E.P.S. shareholder selling 10 million shares (headline: 'Budweiser-maker AB InBev shareholder E.P.S. to sell 10 million shares in company') continues to create supply overhang — stock has declined -2.9% from $80.23 to $77.92 since prior report, confirming ongoing technical pressure; technical momentum is negative with the stock in a downtrend
- Near-term EPS growth deceleration to 9.48% next year (from 22.8% historical) creates a ~18.2x P/E-to-next-year earnings ratio that is less compelling than the 5-year story, and secular alcohol consumption headwinds from health-conscious consumers add structural uncertainty to the 13.4% 5-year EPS growth assumption
Plutrex 10-Factor AI Breakdown
Fundamental Analysis
BUD's fundamentals remain exceptional and unchanged from the prior report. Profitability: gross margin 56.5% (vs. industry 48.91%, +15.5% premium), operating margin 27.34% (vs. industry 22.45%, +21.8% premium), net margin 14.9% (vs. industry 5.90%, +152.5% premium) — the most dramatic peer outperformance of any metric. ROE of 10.71% is 59.4% above the industry average of 6.72%, though modest in absolute terms due to the large equity base from historical acquisitions. Valuation: P/E of 16.78x (down from 17.28x prior report, -2.9%) vs. industry 20.30x; PEG of 1.18 (down from 1.22, -3.3%) vs. industry 1.605 — BUD is the fastest-growing company in its sector trading at the deepest valuation discount. Growth: 5-year EPS CAGR of 13.4% (double industry's 6.67%), next-year EPS growth 9.48% (vs. industry 7.13%), revenue growth 11.0% (vs. industry 0.64%). Financial health: D/E of 0.74 (marginally above industry 0.723, negligible), cash $8.011B, FCF $10.693B — FCF yield of ~13.7% at current price is exceptional. The 12.4 percentage point gap between operating margin (27.3%) and net margin (14.9%) reflects meaningful interest expense from legacy acquisition debt, the primary structural concern.
News Sentiment
Anheuser-Busch InBev, the world's largest brewer, is showing signs of a meaningful comeback — and Wall Street is starting to take notice. The maker of Budweiser, Michelob Ultra, and Corona has been quietly building momentum, with volumes returning to growth after a challenging stretch that included the high-profile Bud Light controversy. According to a recent analysis titled 'AB InBev's Volumes Return to Growth: Is a Bigger Recovery Brewing?', the company is regaining market share across key markets — a critical signal that the brand damage from prior controversies is healing. Adding fuel to the bullish case, Zacks Investment Research just upgraded the stock to a Buy rating (headline: 'Anheuser-Busch Inbev (BUD) Upgraded to Buy: What Does It Mean for the Stock?'), citing improving fundamentals and growth prospects. A separate piece titled '3 Reasons Why Growth Investors Shouldn't Overlook Anheuser-Busch Inbev (BUD)' highlights the company's exceptional free cash flow and double-the-industry earnings growth trajectory. On the ground level, AB InBev is putting money where its mouth is — investing $13 million in its Baldwinsville, New York brewery to expand production of Michelob Ultra and add Cutwater Spirits capabilities, signaling confidence in domestic demand. The one cloud on the horizon: a major shareholder, E.P.S., is selling 10 million shares, creating some near-term selling pressure that has weighed on the stock price. But for patient investors, that pressure may be creating exactly the buying opportunity the fundamentals suggest.
Risk Assessment
Primary risk: E.P.S. 10 million share sale creates near-term supply overhang that has already driven the stock from ~$81.50 (two reports ago) to $77.92 (-4.4%), and the selling may not be complete. If the overhang persists, the stock could test $74-75 support before stabilizing. Secondary risk: near-term EPS growth of 9.48% next year implies a ~18.2x forward P/E, which is less compelling than the 5-year story and could limit near-term re-rating. Structural risk: secular decline in alcohol consumption among younger demographics could impair the 13.4% 5-year EPS growth assumption — this is the most significant long-term risk to the thesis. Mitigation: FCF of $10.693B provides a substantial margin of safety; stop-loss at $72.50 limits downside to ~6.7% from entry midpoint of $77.75, while upside to target_1 ($98.23) is 26.4% — risk/reward of 3.89x is highly favorable. Position size of 3.0% reflects medium conviction appropriate for a quality stock with near-term technical headwinds.
Related Halal Stocks
Related Stocks
Frequently Asked Questions
Is BUD a halal stock?
No, Anheuser-Busch InBev SA/NV (BUD) is currently not classified as halal by AAOIFI criteria.
What is Plutrex's AI rating for BUD?
Anheuser-Busch InBev SA/NV (BUD) has a Plutrex AI rating of 77.0/100 with a Buy consensus, based on a 10-factor analysis covering financial health, growth, valuation, profitability, debt, analyst sentiment, technical momentum, insider confidence, news sentiment, and halal compliance.
Is BUD a good investment?
According to Plutrex AI, BUD has a Buy rating (77.0/100). For the full analysis including trading plan and risk assessment, see the detailed breakdown above.
How can I invest in BUD?
US stocks like BUD can be bought through international brokers such as Interactive Brokers, accessible to Arab investors. Plutrex provides comprehensive analysis plus AI-generated trading plans with entry points, stop losses, and profit targets.
What are the main risks of investing in BUD?
Plutrex AI identifies the main risks for BUD by analyzing valuation, debt, market sentiment, and macro factors. See the Risk Assessment section above for the full breakdown.